Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice (Q45159120)

10 December 2017

Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice (English)

1 reference

10 December 2017

0 references

Martha Campbell-Thompson

6

1 reference

10 December 2017

7

Maria Grant

1 reference

10 December 2017

9

Takahiko Nakagawa

1 reference

10 December 2017

Tomoki Kosugi

1

1 reference

10 December 2017

Takahiro Nakayama

2

1 reference

10 December 2017

Qiuhong Li

3

1 reference

10 December 2017

Vince A Chiodo

4

1 reference

10 December 2017

Li Zhang

5

1 reference

10 December 2017

Byron P Croker

8

1 reference

10 December 2017

16 December 2009

1 reference

American Journal of Physiology - Renal Physiology

10 December 2017

1 reference

10 December 2017

298

1 reference

10 December 2017

3

1 reference

10 December 2017

F609-16

1 reference

Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions

10 December 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Circulating angiogenic factors and the risk of preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Downregulation of p22phox in retinal pigment epithelial cells inhibits choroidal neovascularization in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Uncoupling of the VEGF-endothelial nitric oxide axis in diabetic nephropathy: an explanation for the paradoxical effects of VEGF in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Diabetic kidney disease in thedb/dbmouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00377.2009

10.1152/AJPRENAL.00377.2009

21 January 2018

Identifiers

DOI

1 reference

10 December 2017

1 reference